15 Nov 2013
World Congress on Parkinson's disease & Related Disorders
Britannia Pharmaceuticals is pleased to announce our final congress in 2013, the XX World Congress on Parkinson’s disease and Related Disorders running from 8-11 December 2013 in Geneva, Switzerland.
16 Apr 2013
AM IMPAKT - New clinical trial investigates apomorphine injection for resolving debilitating morning akinesia in Parkinson's disease patients
AM IMPAKT, short for Apokyn for Motor IMProvement of Morning AKinesia Trial, is a Phase IV, multi-center, open-label study investigating treatment with APOKYN (APO-go/Apomine) injection to achieve rapid and reliable improvement of motor symptoms in Parkinson’s disease (PD) patients who experience delayed onset of their oral levodopa medication taken upon awakening.
Britannia Pharmaceuticals, part of the STADA Arzneimittel AG group of companies, is a UK based pharmaceutical company. We specialise in innovative products for chronic and serious medical conditions, and in particular, the treatment of Parkinson’s disease. We are highly committed to improving the quality of life for People with Parkinson's disease.
Our key product Apomorphine Hydrochloride (Brand names: APO-go, APOKYN, Apomine) is a treatment for Parkinson’s disease which is available in many markets through our Distribution or Licensing Partners.